TRICREST

Title: A phase II, single arm, multicentre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer
Disease site: Prostate cancer
Status: Closed

Trial Design: A single arm, phase II, multicentre trial of intramuscular triamcinolone administered monthly in metastatic castration resistant prostate cancer (CRPR). Triamcinolone has putative advantages over commonly used steroids, including lack of weight gain and an inability to stimulate mutated androgen receptors. 55 patients were recruited over 2012-2016 and imaging was performed every 3 months. The primary end point was radiological and symptomatic progression-free survival (PFS). Secondary end points included PSA progression, weight changes and toxicity. Steroid androgenic precursors, cortisol and circulating tumour cells were assessed prior to and 1 month after triamcinolone to see if they correlated with PFS.

Trial details

Chief Investigator: Dr J. Shamash
Trial contact: bci-tricrest@qmul.ac.uk
EudraCT: 2010-022010-32
Sponsor: Barts Health NHS Trust
Participating countries: UK

Publications and presentations

A Phase II Trial of Triamcinolone with Hormone Therapy for Prostate Cancer (TRICREST) in Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer. K. Ng, S.-J. Sarker, M. Greenwood et al. Clinical Oncology 31, 2, E23-E24, February 01, 2019.

Patient friendly information

Cancer Research UK website A trial of triamcinolone with hormone therapy for prostate cancer (TRICREST)

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.

© 2013 ~ 2022 Cancer Research UK Barts Centre